Net sales grew 12% in Q2 2026 excluding currency effects, with strong gains in both Pediatrics and Adult Health segments. Adjusted operating profit rose 32%, and the company maintained high margins and robust cash flow, despite APAC softness. Dividend of SEK 404.6 million was paid.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.